The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments.

Final guidance published today (Thursday 4 December 2025) conditionally recommends seven digital technologies that can support cardiac rehabilitation for adults with cardiovascular disease in the NHS.

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, ...

People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed ...

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma TA1113 3 December 2025 3 December 2025 Talquetamab for treating relapsed and refractory ...

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal ...

This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life. NICE has also produced a ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous ...

There is a simple discount patient access scheme for anhydrous sodium thiosulfate. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can ...